ScreenerHero
AMPHAmphastar Pharmaceuticals, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · amphastar.com
21.87USD+0.60%Mkt Cap: 924.77M $P/E: 12.86

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. I…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap924.77M $
Enterprise Value1.32B $
Revenue (TTM)730.02M $
Gross Profit356.06M $
Net Income (TTM)98.09M $
Revenue/Share16.10 USD
Last Price21.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS03209R1032
Valuation
P/E (Trailing)12.86
P/E (Forward)6.81
PEG—
EV/EBITDA6.79
EV/Revenue1.81
P/S1.26
P/B1.20
EPS (TTM)1.68
EPS (Forward)3.18
52W Range
16.6536% of range31.26
52W High31.26 USD
52W Low16.65 USD
Profitability
Gross Margin49.46%
Oper. Margin21.60%
EBITDA Margin26.65%
Profit Margin13.63%
ROE12.44%
ROA6.02%
Growth
Revenue Growth5.40%
Earnings Growth4.70%
Cash Flow & Leverage
Operating CF156.12M $
CapEx (TTM)37.13M $
FCF Margin31.52%
FCF Yield24.88%
Net Debt398.20M $
Net Debt/EBITDA2.05
Balance Sheet
Debt/Equity0.83
Current Ratio2.40
Quick Ratio1.66
Book Value/Sh18.06 USD
Cash/Share6.820 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.1 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)22.50 USD
Upside (mean)+2.9%
Target Range20.00 USD – 30.00 USD
$20.00+2.9% to mean$30.00
# Analysts6
Ownership
Shares Out.42.54M
Float31.29M
Insiders30.82%
Institutions69.85%
Short Interest
Short Ratio12.3d
Short % Float25.25%
Short % Out.11.59%
Shares Short4.93M
Short (prev mo.)3.85M
Technical
SMA 5019.99 (+9.4%)
SMA 20022.70 (-3.7%)
Beta0.90
S&P 52W Chg18.16%
Avg Vol (30d)434.92K
Avg Vol (10d)538.76K
Technical Indicators
RSI (14)63.7
MACD0.3608
MACD Signal0.2291
MACD Hist.+0.1318
BB Upper21.57 USD
BB Middle20.12 USD
BB Lower18.68 USD
BB Width14.38%
ATR (14)0.8446 USD
Vol Ratio (20d)0.89x